Ractigen Therapeutics obtains $30M to develop RNAa platform

By The Science Advisory Board staff writers

January 28, 2022 -- Ractigen Therapeutics has received $30 million in a series A financing round. Ractigen will use the proceeds to advance several programs from the preclinical to clinical phase as well as to scale up its oligonucleotide manufacturing capabilities.

This latest round follows an $18 million series A investment the company obtained in February 2021.

Ractigen Therapeutics is an early-stage pharmaceutical company focused on the development of technologies to restore gene expression in silenced therapeutic genes. The RNAa technology, according to the company, allows for targeted activation of endogenous gene expression, enabling its use in the treatment of various genetic disorders ranging from monogenic diseases to liver-related indications and cancer.

The company was founded in 2017 by Dr. Long-Cheng Li, Robert Place, PhD, and Moo Rim Kang, PhD.

The series A round was led by SDIC Venture Capital with participation from Eisai, LC Ventures, CSSD Capital, and Xiang He Capital.


Copyright © 2022 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.